SMS Pharmaceuticals Ltd
NSE:SMSPHARMA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
SMS Pharmaceuticals Ltd
Net Issuance of Debt
SMS Pharmaceuticals Ltd
Net Issuance of Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
SMS Pharmaceuticals Ltd
NSE:SMSPHARMA
|
Net Issuance of Debt
-₹67.6m
|
CAGR 3-Years
-67%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Net Issuance of Debt
-₹1.5B
|
CAGR 3-Years
53%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Net Issuance of Debt
-₹729.7m
|
CAGR 3-Years
45%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Net Issuance of Debt
₹22.6B
|
CAGR 3-Years
13%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Lupin Ltd
NSE:LUPIN
|
Net Issuance of Debt
₹23B
|
CAGR 3-Years
67%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Net Issuance of Debt
-₹5.3B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
SMS Pharmaceuticals Ltd
Glance View
SMS Pharmaceuticals Ltd. is a holding company, which engages in the research, development and marketing of active pharmaceutical ingredients. The company is headquartered in Hyderabad, Telangana. The company went IPO on 2007-02-25. The firm is engaged in the business of manufacturing active pharma ingredients (API) and their intermediates. The firm's API products include Ranitidine HCL (Form-2) USP / Ph.Eur, Famotidine USP / Ph. Eur / JP, Pantoprazole Sodium Sesquihydrate US/Ph. Eur, Itraconazole USP / Ph.Eur / JP, Lanoconazole USP / JP, Sumatriptan Succinate USP / Ph.Eur/ BP, Sumatriptan Base USP / Ph.Eur/ BP, Almotriptan Malate, Zolmitriptan, Rizatriptan Benzoate USP/ Ph.Eur, Eletriptan Hydrobromide Monohydrate, Sildenafil Citrate USP / Ph.Eur, Tadalafil USP / Ph.Eur, Vardenafil and others. The firm's manufacturing facilities are located in Bachupally, Hyderabad in the state of Telangana and also at Kandivalasa Village, Poosapatirega Mandal, Vijayanagaram district in Andhra Pradesh. Its research and development (R&D) center is located in Gagillapur, Hyderabad.
See Also
What is SMS Pharmaceuticals Ltd's Net Issuance of Debt?
Net Issuance of Debt
-67.6m
INR
Based on the financial report for Dec 31, 2025, SMS Pharmaceuticals Ltd's Net Issuance of Debt amounts to -67.6m INR.
What is SMS Pharmaceuticals Ltd's Net Issuance of Debt growth rate?
Net Issuance of Debt CAGR 3Y
-67%
The average annual Net Issuance of Debt growth rates for SMS Pharmaceuticals Ltd have been -67% over the past three years .
